Cargando…

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

BACKGROUND: Coronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. Despite the disproportionate incidence of Covid-19 among underserved and racial and ethnic minority populations, the safety and efficacy of the anti–interleukin-6 receptor antibody tocilizumab in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salama, Carlos, Han, Jian, Yau, Linda, Reiss, William G., Kramer, Benjamin, Neidhart, Jeffrey D., Criner, Gerard J., Kaplan-Lewis, Emma, Baden, Rachel, Pandit, Lavannya, Cameron, Miriam L., Garcia-Diaz, Julia, Chávez, Victoria, Mekebeb-Reuter, Martha, Lima de Menezes, Ferdinando, Shah, Reena, González-Lara, Maria F., Assman, Beverly, Freedman, Jamie, Mohan, Shalini V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781101/ https://www.ncbi.nlm.nih.gov/pubmed/33332779 http://dx.doi.org/10.1056/NEJMoa2030340

Ejemplares similares

Institutional tuberculosis infection control in a rural sub-district in South Africa: A quality improvement study
por: Mekebeb, Martha B., et al.
Publicado: (2019)

The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
por: Solomon, Daniel H., et al.
Publicado: (2021)

Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya
por: Shah, Reena, et al.
Publicado: (2022)

Comment on: Benchmarking tocilizumab use for giant cell arteritis
por: Janagan, Shalini, et al.
Publicado: (2022)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

Stevens Johnson Syndrome in a Patient with Giant Cell Arteritis During Short Term Tocilizumab Therapy
por: Venkateswaran, Niranjani, et al.
Publicado: (2020)

531. Risk Factors and Therapeutic Interventions Associated with Mortality in Veterans Diagnosed With SARS-CoV-2 Infection (or COVID-19) Admitted to a Large Academic Medical Center
por: Welch, Elwyn, et al.
Publicado: (2021)

SAT-500 Response to Tocilizumab Retreatment in Refractory Thyroid Eye Disease
por: Kaplan, Daniel, et al.
Publicado: (2020)

Hemodynamic and Pathologic Characterization of the TASK-1(−/−) Mouse Does Not Demonstrate Pulmonary Hypertension
por: Kitagawa, Melanie G., et al.
Publicado: (2017)

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
por: Gale, Sara, et al.
Publicado: (2019)

Tocilizumab and COVID-19
por: Chaudhry, Dhruva, et al.
Publicado: (2020)

Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets
por: Karmouty-Quintana, Harry, et al.
Publicado: (2020)

Association of Glucose-6-Phosphate Dehydrogenase Deficiency With Outcomes in US Veterans With COVID-19
por: Elsea, Sarah H., et al.
Publicado: (2023)

Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis
por: Reiss, William G., et al.
Publicado: (2015)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

Tocilizumab: Neutropenia: case report
Publicado: (2020)

Günstige Effekte von Tocilizumab
por: Diener, Hans-Christoph
Publicado: (2020)

Papulopustular Rash Due to Tocilizumab
por: Kohro-Kawata, Junko, et al.
Publicado: (2019)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Tocilizumab ohne überzeugende Wirkung
por: Diener, Hans-Christoph
Publicado: (2021)

Cases of pancreatitis reported with tocilizumab
Publicado: (2021)

Time for tocilizumab in COVID-19?
por: Butler, Ethan, et al.
Publicado: (2021)

Tocilizumab: Neutropenia: case report
Publicado: (2021)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
por: Sarhan, Neven Mohamed, et al.
Publicado: (2023)

Twik‐2(−/−) mouse demonstrates pulmonary vascular heterogeneity in intracellular pathways for vasocontractility
por: Kitagawa, Melanie G., et al.
Publicado: (2019)

Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis
por: Geffin, Ryan, et al.
Publicado: (2023)

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
por: Mikulska, Malgorzata, et al.
Publicado: (2020)

Correction: Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
Publicado: (2019)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

Integrated safety in tocilizumab clinical trials
por: Schiff, Michael H, et al.
Publicado: (2011)

Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy
por: van Duin, David, et al.
Publicado: (2011)

Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014)

Tocilizumab: A Review in Rheumatoid Arthritis
por: Scott, Lesley J.
Publicado: (2017)

Tocilizumab for the Treatment of Mevalonate Kinase Deficiency
por: Rafiq, Nadia K., et al.
Publicado: (2018)

Successful treatment of Behçet’s uveitis with Tocilizumab
por: Alokaily, F., et al.
Publicado: (2017)

Thromboinflammation response to tocilizumab in COVID‐19
por: Gergi, Mansour, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l8cbsii8mo879q0niel578pgfh